Show me a biotech CEO that is not talking about deals. It's a load of crock, most are way too early. Why is Campbell any different? Just got a hunch? I invest almost exclusively in biotech companies and I am happy to be sceptical about what the Companies I invest in and what they are saying, because they all pump the same lines - high unmet medical need, best in class, partnerships etc etc.
Reality is that a deal is much more likely further down the track than after GMP.
Ann: Presentation to highlight broader potential of Deoxymabs, page-69
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
-0.001(6.25%) |
Mkt cap ! $15.43M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.8¢ | $4.313K | 575K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 8536128 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 2418923 | 6 |
View Market Depth
| Last trade - 13.50pm 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.8¢ |
Change
-0.001 ( 7.14 %) |
||||
| Open | High | Low | Volume | ||
| 0.7¢ | 0.8¢ | 0.7¢ | 1800000 | ||
| Last updated 13.50pm 22/05/2024 ? | |||||
| PAB (ASX) Chart |